PE20030363A1 - Utilizacion de sistemas de indan-1-ol varias veces sustituidos, para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad - Google Patents

Utilizacion de sistemas de indan-1-ol varias veces sustituidos, para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Info

Publication number
PE20030363A1
PE20030363A1 PE2002000812A PE2002000812A PE20030363A1 PE 20030363 A1 PE20030363 A1 PE 20030363A1 PE 2002000812 A PE2002000812 A PE 2002000812A PE 2002000812 A PE2002000812 A PE 2002000812A PE 20030363 A1 PE20030363 A1 PE 20030363A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
obesity
preparation
treatment
Prior art date
Application number
PE2002000812A
Other languages
English (en)
Inventor
Martin Bickel
Volker Krone
Gerhard Jaehne
Matthias Gossel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20030363A1 publication Critical patent/PE20030363A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A LA UTILIZACION DE SISTEMAS DE INDAN-1-OL VARIAS VECES DE FORMULA I DONDE R1-R4 SON H, F, Cl, Br, I, CN, N3, NO2, OH, OALQUILO (C1-C8), OCICLOALQUILO(C3-C8), O-CICLOALQUILO C3-C8, O-CH2-FENILO, ENTRE OTROS; R2 Y R3 JUNTOS FORMAN EL RADICAL -O-CH2-O-; X ES S, SO, SO2; Y ES (CH2)p DONDE p PUEDE SER 0-3; R5 ALQUILO C1-C18, CICLOALQUILO C3-C4, CICLOALQUILO C6-C8, DONDE LOS GRUPOS ALQUILO PUEDEN ESTAR REEMPLAZADOS CON F, (CH2)1-6-COOH, ENTRE OTROS; R6 ES (CH2)0-6-R9, (CH2)0-6-COO-ALQUILO C1-C6, (CH2)0-6-CONH2, ENTRE OTROS; R7 ES (CH2)0-4-R12, H, ALQUILO C1-C12, CICLOALQUILO C3-C4, CICLOALQUILO C3-C8, COO-ALQUILO C1-C6, ENTRE OTROS; R8 ES (CH2)0-4-R14, ALQUILO C1-C12, CICLOALQUILO C3-C4, CICLOALQUILO C6-C8, ENTRE OTROS; R9, R12 Y R14 SON FENILO, 1-, 2-NAFTILO, BIFENILO, UN RADICAL HETEROCICLICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. SON COMPUESTOS PREFERIDOS 5-CLORO-2-FLUORO-2-METANOSULFANIL-INDAN-1-OL, 5-CLORO-2-FLUORO-2-METANOSULFONIL-1-TRIFLUOROMETIL-INDAN-1-OL. LOS COMPUESTOS MENCIONADOS SON UTILES COMO UTILES PARA EL TRATAMIENTO Y PROFILAXIS DE LA OBESIDAD
PE2002000812A 2001-08-31 2002-08-23 Utilizacion de sistemas de indan-1-ol varias veces sustituidos, para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad PE20030363A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10142659A DE10142659A1 (de) 2001-08-31 2001-08-31 Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas

Publications (1)

Publication Number Publication Date
PE20030363A1 true PE20030363A1 (es) 2003-06-09

Family

ID=7697230

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000812A PE20030363A1 (es) 2001-08-31 2002-08-23 Utilizacion de sistemas de indan-1-ol varias veces sustituidos, para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Country Status (10)

Country Link
US (3) US6686397B2 (es)
EP (1) EP1425000B1 (es)
JP (1) JP2005507382A (es)
AU (1) AU2002333447B2 (es)
CA (1) CA2458553A1 (es)
DE (1) DE10142659A1 (es)
IL (1) IL160600A0 (es)
MX (1) MXPA04001847A (es)
PE (1) PE20030363A1 (es)
WO (1) WO2003020255A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142661B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
JP4774763B2 (ja) * 2004-03-25 2011-09-14 住友化学株式会社 精製酢酸３−メチル−２−ブテニルの製造方法
US20050257715A1 (en) * 2004-04-08 2005-11-24 Christophe Dumousseaux Compositions for application to the skin, to the lips, to the nails, and/or to hair
US20050238979A1 (en) * 2004-04-08 2005-10-27 Christophe Dumousseaux Compositions for application to the skin, to the lips, to the nails, and/or to hair
FR2876011B1 (fr) 2004-10-05 2006-12-29 Oreal Procede de maquillage d'un support et kit pour la mise en oeuvre de ce procede
US9649261B2 (en) 2004-10-05 2017-05-16 L'oreal Method of applying makeup to a surface and a kit for implementing such a method
ES2333241T3 (es) * 2004-10-05 2010-02-18 L'oreal Kit y procedimiento de maquillaje.
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
FR2888115B1 (fr) * 2005-07-08 2013-02-15 Oreal Fond de teint liquide, procede de maquillage et kit pour la mise en oeuvre d'un tel procede.
FR2889921B1 (fr) 2005-08-30 2007-12-28 Oreal Ensemble de conditionnement et d'application comportant un dispositif magnetique.
DE102013009631A1 (de) * 2013-06-10 2014-12-11 Forschungszentrum Jülich GmbH Verfahren zur Herstellung von Cathin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2345146C3 (de) 1973-09-07 1981-08-06 Feinmechanische Werke Mainz Gmbh, 6500 Mainz Hydraulischer Stellantrieb
FR2345146A1 (fr) * 1976-03-23 1977-10-21 Logeais Labor Jacques Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol
DE2965279D1 (en) * 1978-07-27 1983-06-01 Schering Ag Indanyl derivatives, process for their preparation and pharmaceutical compositions containing these compounds
DE3103372A1 (de) * 1981-01-27 1982-09-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue indanyl-derivate, ihre herstellung und verwendung
EP0874800B1 (en) * 1995-12-06 2003-08-06 Venantius Limited Indane dimer compounds with smooth muscle relaxing and/or mast cell stabilising and/or antiinflammatory activity
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
EP0958296B1 (en) 1996-12-31 2003-07-30 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
US5987946A (en) 1997-08-15 1999-11-23 Watts; James A. Lock picking method and apparatus
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
PL357547A1 (en) * 2000-02-23 2004-07-26 Aventis Pharma Deutschland Gmbh 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents
DE10142662B4 (de) * 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142661B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US20030130323A1 (en) 2003-07-10
MXPA04001847A (es) 2004-06-15
WO2003020255A1 (de) 2003-03-13
JP2005507382A (ja) 2005-03-17
EP1425000A1 (de) 2004-06-09
US6686397B2 (en) 2004-02-03
DE10142659A1 (de) 2003-03-20
AU2002333447B2 (en) 2006-10-26
US6812257B2 (en) 2004-11-02
CA2458553A1 (en) 2003-03-13
US6812256B2 (en) 2004-11-02
EP1425000B1 (de) 2012-08-01
US20040092488A1 (en) 2004-05-13
US20040106583A1 (en) 2004-06-03
IL160600A0 (en) 2004-07-25

Similar Documents

Publication Publication Date Title
PE20030363A1 (es) Utilizacion de sistemas de indan-1-ol varias veces sustituidos, para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
PE20020858A1 (es) Indanil aminas aciladas
PE20070078A1 (es) Compuestos heterociclicos macrociclicos como inhibidores de aspartil proteasa
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
PE20060562A1 (es) Derivados de amino-piperidina como agonistas de los receptores de melanocortina mc3 y/o mc4
PE20020483A1 (es) Peptidos ciclicos selectivos como agonistas de los receptores de melanocortina 4
PE20020195A1 (es) AGONISTAS ß3 ADRENERGICOS
PE34297A1 (es) Ligandos especificos del neuropeptido y1
PE20081448A1 (es) Inhibidores de transcriptasa inversa no nucleosidicos
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20030762A1 (es) Compuestos heterociclicos como antagonistas nk1
PE20050460A1 (es) COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
PE20071245A1 (es) COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs)
PE20020870A1 (es) 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas
UY28150A1 (es) Agentes terapeuticos
PE20060459A1 (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
PE20080144A1 (es) Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
CO5640041A2 (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
PE20080136A1 (es) Arilsulfonamidas sustituidas como agentes antivirales
AR053340A1 (es) Derivados de trifluormetilbenzamida y sus usos terapeuticos

Legal Events

Date Code Title Description
FD Application declared void or lapsed